Condition: Rheumatoid Arthritis · Major Adverse Cardiac Events · Sponsor: Shaikh Zayed Hospital, Lahore
The rationale of our study is to observe the incidence of MACE in RA patients treated with tofacitinib along with statins with one or more cardiovascular disease risks. PRIMARY OBJECTIVE * To determine the incidence of MACE in Rheumatoid Arthritis patients with moderate to high disease activity and with one or more cardiovascular disease risks, which are non-responsive to standard conventional DMARDs (cDMARDs) treatment and are prescribed Tofacitinib 5 mg twice daily along with statin 20 mg daily versus TNF Inhibitors. * The study aim to compare MACE in RA patients treated with tofacitinib and statin versus TNF inhibitors.
This description comes directly from the study's public registry record.
Masooma Hashmat, FCPS Rheumatology · +923353053304 · masoomahashmat@gmail.com
Aflak Rasheed, FCPS Rheumatology · +923009476913 · aflakrasheed@yahoo.com
Always discuss trial participation with your own doctor first.
| Shaikh Zayed Hospital, Lahore | Lahore, Punjab Province, Pakistan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07554820